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Editorial
Although sickle cell disease was designated by a number of onomatopoetic native
names in Africa for centuries (1 ), it was clearly described as a distinct hematologi-
cal and clinical entity in the United States in 1910 (2). During the next three
decades, a considerable body of descriptive, clinical, and genetic data was slowly
accumulated; but progress accelerated after protein chemists such as Pauling and
Itano and later Ingraam, indentified the molecular defect in sickle hemoglobin. The
far-reaching significance of the delineation of the basic molecular defect in sickle
cell anemia can hardly be overstated, for it has been decisive in the delineation of
the mechanisms of gene action and a deciphering of the genetic code. It is now pos-
sible to describe a fairly precise sequence from the substitution of base pairs in
DNA which ultimately results in the clinical symptomatology of the patient. From
the point of view of biochemical genetics and protein chemistry, sickle cell disease
is one of the best understood of human diseases.
Unfortunately, this sophisticated information has made little impact on the man-
agement of the patient with sickle cell anemia. A substantial number of patients
die in their first five years, and survival beyond the third decade is unusual. In
addition, recurrent painful or vasocclusive crises, for which there is no specific
therapy, plague the life of the sickle cell patient. Treatment of sickle cell anemia
has progressed very little during the past 25 years. Symptomatic management in-
cluding hydration, analgesia and blood transfusions remain the mainstays of
therapy. More specific treatment has been elusive, but recent events in this area
are of considerable interest.
Studies of molecular aspects of the sickling phenomenon have indicated the im-
portance of intramolecular hydrophobic bonds (3). Hydrophobic bonds can be
disrupted by concentrated solutions of urea, and this fact led Dr. Robert Nalbandian
to believe that urea might be a therapeutic modality. He infused concentrated solu-
tions of urea into several patients experiencing painful sickle cell crises. Apparent
clinical improvement was noted following these infusions.
Objections to this therapy were immediately raised. First, in order to disrupt
hydrophobic bonds, the concentration of urea must approach 1 M. In a patient this
is equivalent to a blood urea nitrogen of over 5000 mg/100 ml! Blood levels ac-
complished during urea infusions were less than a tenth of this concentration.
Clinicians experienced in the management of sickle cell disease have long recog-
nized the extreme variability of the painful sickle cell crisis. This makes controlled
observations crucial before judging efficacy of any form of therapy. The history of
sickle cell disease is studded with scores of therapies which were originally de-
scribed as being of great benefit, but when suitable controlled studies were per-
formed, they were found to be of no consistent value.
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Despite the facts that the proposed mechanism for action of urea could not be
operative, and that its presumed efficacy was based on a few anecdotal descriptions,
a virtual avalanche of publicity was released. Press conferences and released maga-
zine articles, letters to editors and articles in medical newsletters were written, the
theme of which was that urea was rational, effective therapy based on molecular
pathogenesis. The flurry of excitement that greeted these releases was heightened
because sickle cell disease had become a politically important issue, even being
specifically identified in a State of the Union message by President Nixon.
Inevitably, in large part because of the publicity, it became necessary to rapidly
embark upon a prospective and very expensive study of the effectiveness of urea
therapy for the painful crises of sickle cell disease. This study has recently been
completed. Its results decisively indicate that urea is of no greater value than simple
hydration (4).
One interesting spin-off of the urea affair has been the discovery of cyanate as
possible therapy. Cerami and Manning at the Rockefeller Institute recognized that
at the blood levels obtained, therapeutical urea could not inhibit sickling; therefore,
they considered possible alternate mechanisms for possible in vivo effects. Urea
has long been known to disassociate into small amounts of active cyanate. Cyanate
reacts with proteins by a process called carbamylation. Cerami and Manning found
that cyanate had a high affinity for reaction with the N terminal valine of the beta
chain of hemoglobin, and Hb S molecules which have been carbamylated lose their
capacity to sickle. In addition to a strong in vitro antisickling effect of cyanate,
Cerami and Manning were able to demonstrate that cyanate treatment of Hb SS
red cells doubled their in vivo survival. Here was unequivocal evidence of inhibition
of the sickling process in the patient's own circulation. The mechanism by which
cyanate prevents sickling has not been established. A large scale, carefully designed
study of cyanate therapy will soon be started. This will not only assess its value in
preventing painful crises, but also detect possible toxicity. The logical and profes-
sional approach of the scientists who have conceived and developed cyanate therapy
contrasts strikingly with that which was observed with urea.
Research in sickle cell anemia has been inhibited by the lack of a suitable animal
system for study. The development by Castro, Orlin, and Finch of a method for
accurately estimating survival of human red cells in rodents in which a state of
R. E. blockade has been induced, may provide a potent tool for assessing a variety
of human hemolytic states, including sickle cell anemia.
In investigations reported in this issue, they describe the effects of cyanate on
survival of human Hb SS red cells. They confirm, in their animal system, that
carbamylated red cells have increased survival. However, when the recipient rates
were made hypoxic, beneficial effects of cyanate were much less evident. This may
indicate a heterogenity of human sickle red cells in terms of either oxygen sensitivity
or alternatively to susceptibility to carbamylation. If there is a close analogy to
the behavior of sickle cells in Castro. Orlin, and Finch's rats and their behavior
in the patient's circulation, their findings do cast some doubt on the long-term
beneficial value of cyanate therapy in patients. This neat model should provide
a potent tool for exploring therapeutic modalities in this disease. Ultimately, con-
trolled clinical studies are necessary for evaluation, but these valid animal systems
could hasten the:r testing and increase the likelihood of their ultimate therapeutic
success,
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